Omalizumab: new addition to dermatologic therapy for chronic spontaneous/idiopathic urticaria

Authors

  • Zahida Rani
  • Bushra Bashir
  • Ijaz Hussain

References

Zuberbier T, Aberer W, Asero R et al. The EAACI/ GA(2)LEN/ EDF/ WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014;69:868- 87

Urgert MC, van den Elzen MT, Knulst AC et al. Omalizumab in patients with spontaneous urticaria: a systemic review and GRADE assessment. Br J Dermatol. 2015;173:404-415.

Saini SS, Bindslev-Jensen C, Maurer M et al. Efficacy and safety of omalizumab in patients with chronic idiopathic/ spontaneous urticaria who remain symptomatic on H1 antihistamines: a randomized, placebo-controlled study. J Invest Dermatol. 2015;135:67-75.

Maurer M, Rosen K, Hsieh H-J et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368:924-35.

Kaplan A, Ledford D, Ashby M et al. Omalizumab in patients with symptomatic chronic idiopathic/ spontaneous urticaria despite standard combination therapy. J Allergy Clin Immunol. 2013;132:101-9.

Saini S, Rosen KE, Hsieh H-J et al. A randomized, placebo-controlled, doseranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol. 2011;128:567-73.e1.

Maurer M, Altrichter S, Bieber T et al. Efficacy and safety of omalizumab patients with chronic urticaria who exhibit IgE against thyroperoxidase. J Allergy Clin Immunol. 2011;128:202-9.e5.

Kaplan A, Ferrer M, Bernstein JA et al. Timing and duration of omalizumab response in patients with chronic idiopathic/spontaneous urticaria. J Allergy Clin Immunol. 2015 Oct 16. pii: S0091- 6749(15)01247-6. doi: 10.1016/j.jaci.2015.08.023. [Epub ahead of print]

Casale TB, Bernstein JA, Maurer M et al. Similar efficacy with omalizumab in chronic idiopathic/spontaneous urticaria despite different background therapy. J Allergy Clin Immunol Pract. 2015;3:743-5.

Xolair (omalizumab) prescribing information; 2014. Available from: http://www.gene.com/gene/products/informa tion/pdf/xolair-prescribing.pdf. Accessed on September 17, 2015.

Downloads

Published

2016-11-26

How to Cite

1.
Rani Z, Bashir B, Hussain I. Omalizumab: new addition to dermatologic therapy for chronic spontaneous/idiopathic urticaria. J Pak Assoc Dermatol [Internet]. 2016Nov.26 [cited 2024Dec.8];25(4):249-51. Available from: https://www.jpad.com.pk/index.php/jpad/article/view/139

Most read articles by the same author(s)

<< < 3 4 5 6 7 8 9 10 11 12 > >>